ANNUAL REPORT 2024

DAMON RUNYON
CANCER RESEARCH
FOUNDATION

WHAT WILL AI MEAN FOR CANCER RESEARCH?

With the rise of single-cell sequencing and high-resolution imaging, the completion of The Cancer Genome Atlas, and increasingly large biobanks of patient tissue samples, the past decade has generated an unimaginable amount of data about cancer. On their own, these data are just numbers and letters—but the patterns they contain are revealing. What features are shared among blood cells that develop into leukemia? Which slow-growing lymphomas are most likely to become aggressive? Which brain tumors will respond to a given therapy, and which will resist treatment?

THE ANSWERS MAY BE HIDDEN IN PLAIN SIGHT.

We've all heard a lot about the potential of artificial intelligence (AI) to save or replace humanity, depending on whom you ask. On one point, we can agree: there are many things that humans can do better than machines, but when tasked with finding a pattern, computers excel. And as biologists have been amassing data, computer science has been advancing in parallel.

"NOWADAYS, WE'RE NOT LIMITED BY COMPUTATIONAL POWER," SAYS DAMON RUNYON QUANTITATIVE BIOLOGY FELLOW TAL EINAV, PhD, "BUT BY OUR CREATIVITY IN HOW WE APPLY IT TO RESEARCH QUESTIONS."

Our scientists are exceptionally creative. In this report, you will learn how Damon Runyon scientists are currently applying the tools of artificial intelligence to advance the detection, prevention, and treatment of cancer. As you will see, whether by detecting ovarian cancer before it spreads or predicting a given patient's response to immunotherapy, these tools are already improving cancer care.

GIVEN ENOUGH DATA, COMPUTERS ARE SPECTACULAR AT EXTRAPOLATING FROM THE PAST TO MAKE PREDICTIONS ABOUT THE FUTURE.

Most of us encounter such predictions every day—which word we will type next, which new song we might like, what the weather tomorrow will be.

These predictions may not always impact our choices.

BUT HOW MIGHT WE RESPOND IF A COMPUTER COULD PREDICT OUR RISK OF DEVELOPING CANCER?

This is what Damon Runyon Clinical Investigator Lachelle D. Weeks, MD, PhD, aims to find out.

LACHELLE D. WEEKS, MD, PhD
Damon Runyon-Timmerman Traverse Clinical Investigator
Dana-Farber Cancer Institute

In her lab at Dana-Farber Cancer Institute, Dr. Weeks is building a computerized model that can predict a patient's risk of developing acute myeloid leukemia based on images of their blood cells. She hopes this type of screening will one day become routine for patients who, due to their age or family history, may be at high risk.

"Traditionally, when folks are diagnosed with acute myeloid leukemia, we know because they come into the emergency room in crisis, with bleeding, or severe infection, or abnormally high or low blood counts," Dr. Weeks says. "That is the first time that most patients even hear the diagnosis said aloud."

Roughly 15% of adults over the age of 65 have a condition known as clonal hematopoiesis (CH), meaning they harbor mutations in their blood that are associated with blood cancer, but they do not yet have cancer. Most of these individuals will never develop cancer. It remains unclear what distinguishes the minority who do.

Right now, Dr. Weeks' team is in data collection mode. Every patient who comes into the clinic and consents to the protocol has a blood sample drawn and put through a high-resolution imaging tool called Cellavision. (The Weeks lab is also collecting samples from community sites and MD Anderson Cancer Center to ensure a diverse dataset.) Provided with thousands of images of blood cells, the computer's task is to detect patterns among patients who develop leukemia—features too small to see under a microscope, like minute changes in cell size or nuclear shape.



"About 60 million adults in the U.S. are considered at-risk because of this precursor condition," Dr. Weeks explains. "I envision this algorithmic approach as a way to shrink that number and really hone in on the highest-risk individuals."

Knowing your risk level not only enables earlier cancer detection, but may one day qualify you for a preventative intervention. At Washington University, **Damon Runyon Clinical Investigator Kelly Bolton, MD, PhD**, is currently enrolling CH patients in clinical trials of two drugs, enasidenib and ivosidenib, that target specific blood cell mutations. If successful, they would be the first genetically targeted preventative therapies for cancer.

"A lot of the most cutting-edge science is funded at the foundation level," says Dr. Weeks. "To get NIH grants, you have to be working on something that already exists. For labs like mine, where we are working on something that isn't here yet—that is, a screening for blood cancer—Damon Runyon funding is critical for survival and progress."

EARLY DETECTION OF A TUMOR IS OFTEN THE REASON CANCER TREATMENT WORKS.

But some tumors, like ovarian cancer, show few early signs, allowing the cancer to spread significantly before it is caught. In cases where our best approach right now is to "wait and see," artificial intelligence may be the first to raise a red flag.



“THIS MAY SOUND LIKE SCIENCE FICTION, BUT WE’RE WORKING TO MAKE IT REALITY,”



says former Damon Runyon Fellow Daniel A. Heller, PhD, of Memorial Sloan Kettering Cancer Center.

DANIEL A. HELLER, PhD
Head of Cancer Nanomedicine Laboratory
Memorial Sloan Kettering Cancer Center

The Heller lab has developed an implantable sensor that can detect proteins associated with ovarian cancer and send a signal to a device worn outside the body. The sensor is designed to be implanted in the uterus or the fallopian tubes, where the concentration of these proteins is highest, and attached to antibodies that bind the proteins of interest. If bound, the sensor, trained by a machine-learning algorithm to recognize the cancer’s molecular “fingerprint,” sends a signal to the wearable device.

The Heller lab has already demonstrated that their sensor can detect ovarian cancer in mice and is now conducting their first tests in human uteri removed

during surgery. If successful, the sensor could serve as a rapid screening tool for patients with higher genetic risk of ovarian cancer. It would also benefit patients undergoing cancer treatment, enabling them to monitor disease progression without frequent trips to the doctor or anxious waiting periods between scans.

"Right now, it's hard to tell if a patient has an aggressive cancer or if it's safe to wait a while before another scan," Dr. Heller says. "If you could see a change in biomarker levels in hours or days, it could give physicians an earlier warning."

Meanwhile, at Stanford University, Damon Runyon scientists **Kavita Y. Sarin, MD, PhD**, and **Adam de la Zerda, PhD**, are using AI to tackle the opposite problem: cancers that are plainly visible but hard to distinguish from benign growths. Aiming to spare patients the dermatologist's scalpel, the pair recently unveiled a "virtual biopsy" tool to diagnose skin cancer.

The imaging device sends light waves into the skin with a laser and, based on how the light waves bounce off the cells, creates a high-resolution, three-dimensional reconstruction of the tissue. (This is also how ophthalmologists scan the back of the eye.)

NONINVASIVE VIRTUAL BIOPSY



The team then used AI to convert these scans into images that resemble traditional pathology slides, making them readable by doctors trained in standard diagnostic protocols. The goal is to enable clinicians to incorporate the tool into their practice, reducing unnecessary biopsies.

A physician herself, Dr. Sarin is particularly excited about how AI will enhance her ability to deliver personalized patient care.

Image: Winetraub Y, Van Vleck A, Yuan E, Terem I, Zhao J, Yu C, Chan W, Do H, Shevidi S, Mao M, Yu J, Hong M, Blankenberg E, Rieger Ke, Chu S, Aasi S, Sarin Ky, De La Zerda A. Noninvasive Virtual Biopsy Using Micro-Registered Optical Coherence Tomography (OCT) In Human Subjects. *Sci Adv.* 2024 Apr 12.

KAVITA Y. SARIN, MD, PhD
Damon Runyon-D.G. 'Mitch' Mitchell
Clinical Investigator
Stanford University

"Each scientist brings a unique perspective on how to leverage its potential," says Dr. Sarin. "By funding a wide range of scientists, and encouraging creativity and exploration, Damon Runyon fosters breakthrough applications that might not emerge from industry-driven AI efforts, which often prioritize profitability."

In today's cancer treatment landscape, immunotherapies are increasingly offered as a less toxic alternative to chemotherapy and radiation.

UNFORTUNATELY, IMMUNOTHERAPIES DO NOT WORK FOR ALL PATIENTS, AND IT IS HARD TO PREDICT WHO WILL BENEFIT FROM THEM.

Hard for humans, that is.



ELIEZER M. VAN ALLEN, MD
Chief of the Division of Population Sciences
Dana-Farber Cancer Institute

At Dana-Farber Cancer Institute, former Damon Runyon Clinical Investigator Eliezer M. Van Allen, MD, and his team have employed an AI-based tool to help answer the question:

"WHAT DOES A KIDNEY TUMOR THAT RESPONDS TO IMMUNOTHERAPY LOOK LIKE?"

Pathologists routinely assess tumor samples on pathology slides to identify key disease features, including how tumor cells deviate from normal cells. Dr. Van Allen's team initially trained their AI tool to do just this, but soon found it capable of much more—of measuring, for instance, *variation* in disease features across tumor samples.

Encouraged, the team expanded their deep learning model to quantify tumor microheterogeneity, which measures the extent to which cancer cells vary across a sample, and immune infiltration, or how deeply immune cells have penetrated the tumor. Although these measures can be manually determined by pathologists, they are prohibitively time-consuming for routine use.

To explore the predictive potential of these measurements, the researchers applied their tool to pathology slides from kidney cancer patients receiving immunotherapy as part of a clinical trial.



TUMOR HETEROGENEITY



The tool found that higher levels of tumor microheterogeneity and deeper immune infiltration were associated with better outcomes.

“These signals are hiding in plain sight,” says Dr. Van Allen. “They are just hard for pathologists to practically measure on individual slides. With AI, we have a scalable way to potentially squeeze a lot more information out of these slides.”



IMMUNE INFILTRATION

A patient may soon be able to have their tumor scanned by this tool to determine if they are a good candidate for immunotherapy. This is one example among many—in the Van Allen lab alone—of how AI might be used to inform cancer treatment decisions.

At MD Anderson Cancer Center in Houston, Damon Runyon scientists **Xiuning Le, MD, PhD, John V. Heymach, MD, PhD**, and **Natalie Vokes, MD**, have developed a model that analyzes chest CT scans to predict how a patient with lung cancer will respond to immune checkpoint inhibitors. This model, they found, predicted survival better than conventional risk factors, such as smoking status, or tissue irregularities seen under a microscope. They are now working on a model to predict how lung tumors will respond to tyrosine kinase inhibitors, a common targeted therapy.

But it will still be a while, Dr. Van Allen clarified, before clinicians use such models to "pick which drugs for which patients."

"The more imminent technologies in that domain are diagnostics," he says. "Determining what kind of cancer, and what stage it has reached—those kinds of models are moving more quickly."

EVEN AS WE MARVEL AT THE POTENTIAL OF THESE TOOLS TO REVOLUTIONIZE CANCER CARE, IT MUST BE SAID THAT THEIR UTILITY GOES ONLY AS FAR AS THE THOUGHTFULNESS OF THEIR CREATORS.

"It's easy to train a model—any computer science student can do it," says **Damon Runyon Quantitative Biology Fellow Jakob Wirbel, PhD,** at Stanford University, "It's hard to know if your model is good and if you can actually learn something from it. For this, we need researchers at the intersection of computer science and biology, who can make sense of the methods and understand the biological implications."

"Damon Runyon is right at the forefront with the Quantitative Biology Fellowship—to my knowledge the only one of its kind—intentionally recruiting super talented computer scientists, physicists, and mathematicians, and steering them to cancer research questions," says Dr. Van Allen.

"Or take Dr. Weeks," he continued, referring to his colleague featured on page 3. "She's coming at this from a different angle, as a physician-scientist with an innovative idea, and with Damon Runyon support she's able to use this technology to pursue the questions she cares about."

Since 1946, the Damon Runyon Cancer Research Foundation has been at the vanguard of cancer research technology, from the first method of growing human cells in culture to the first genome editing tools. Now, our scientists are becoming leaders in the era of artificial intelligence, showing us how these tools can be used responsibly for the benefit of cancer patients.

"AI may help scientists be more efficient. But to generate biological knowledge and therapeutic outcomes, we will always still need human researchers," says Dr. Wirbel.

Thank you for supporting the humans behind the computers.



100% OF YOUR DONATIONS GO DIRECTLY TO BRAVE AND BOLD CANCER RESEARCH.

Since its founding in 1946, in partnership with donors across the nation, the Damon Runyon Cancer Research Foundation has invested nearly $450 million and funded nearly 4,000 scientists.

We currently support 180 researchers at over 50 institutions across the world.

We pay our low overhead from Damon Runyon Broadway Tickets and our endowment.

To learn more, visit damonrunyon.org.

BOARD OF DIRECTORS

CHAIR

Andrew S. Rachleff
Chairman
Wealthfront Inc.
PALO ALTO, CALIFORNIA

VICE CHAIR

Scientific Programs

William G. Kaelin, Jr., MD
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute and Harvard Medical School
Howard Hughes Medical Institute Investigator
BOSTON, MASSACHUSETTS

TREASURER

Laurence W. Cohen
Founder, Partner and CEO
Seven Bridges Advisors, LLC
NEW YORK, NEW YORK

SECRETARY

Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth & Zabel LLP
NEW YORK, NEW YORK

Carlos L. Arteaga, MD
Director of the Harold C. Simmons Comprehensive Cancer Center
Associate Dean of Oncology Programs
Annette Simmons Distinguished University Chair in Breast Cancer Research
University of Texas Southwestern Medical Center
DALLAS, TEXAS

David M. Beirne
General Partner
X^{10} Capital
SAN FRANCISCO, CALIFORNIA

Melissa L. Cohn
Regional Vice President
William Raveis Mortgage LLC
DELRAY BEACH, FLORIDA

Deborah J. Coleman
BOSTON, MASSACHUSETTS

Robyn Coles
President
TRATE Properties, LLC
NEW YORK, NEW YORK

Gary E. Erlbaum
President
Greentree Properties
ARDMORE, PENNSYLVANIA

Buck French
General Partner
X^{10} Capital
SAN FRANCISCO, CALIFORNIA

Elaine Fuchs, PhD
Laboratory Head, Laboratory of Mammalian Cell Biology & Development
Rebecca C. Lancefield Professor
The Rockefeller University
Howard Hughes Medical Institute Investigator
NEW YORK, NEW YORK

Levi A. Garraway, MD, PhD
Executive Vice President
Head of Global Product Development
Chief Medical Officer
Genentech/Roche
SOUTH SAN FRANCISCO, CALIFORNIA

Richard B. Gaynor, MD
President and Chief of Research & Development
BioNTech US, Inc.
CAMBRIDGE, MASSACHUSETTS

Erica Evans Gioffre
Management Committee Member
Hirtle, Callaghan & Company
WEST CONSHOHOCKEN, PA

DAMON RUNYON

BOARD OF DIRECTORS

Todd R. Golub, MD
Director and Founding Core Institute Member
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Professor of Pediatrics
Harvard Medical School
CAMBRIDGE, MASSACHUSETTS

David A. Gordon, PhD
Strategist
Bridgewater Associates
WESTPORT, CONNECTICUT

Scott Greenstein
President and Chief Content Officer
SiriusXM
NEW YORK, NEW YORK

Morana Jovan-Embiricos, PhD
Managing Partner
F2 Capital Ventures LLP
LONDON, UNITED KINGDOM

Steven A. Kandarian
Chairman, President and Chief Executive Officer (retired)
MetLife, Inc.
NORTH PALM BEACH, FLORIDA

Noah Knauf
General Partner
Bond Capital
SAN FRANCISCO, CALIFORNIA

Gabrielle Layton, PhD
PALO ALTO, CALIFORNIA

David G. Marshall
Chairman and Chief Executive Officer
Amerimar Realty Company
PHILADELPHIA, PENNSYLVANIA

Gerald M. Marshall
President and Chief Executive Officer
Netrality Data Centers
Chairman and Chief Executive Officer
Amerimar Enterprises, Inc.
MIAMI BEACH, FLORIDA

Richard W. Meier
Director
The Bakewell Foundation
ST. LOUIS, MISSOURI

Richard J. O'Reilly, MD
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Joseph Pearlberg, MD, PhD
Vice President of Scientific Affairs on the Therapeutics Team
Deerfield Management Company
NEW YORK, NEW YORK

Lori J. Pierce, MD
Professor, Radiation Oncology
University of Michigan Rogel Cancer Center
ANN ARBOR, MICHIGAN

Adam R. Schwartz
Managing Partner and Global Head of Real Estate
TPG Angelo Gordon
NEW YORK, NEW YORK

Michael V. Seiden, MD, PhD
Chief Executive Officer and Co-founder
Gladius Therapeutics
THE WOODLANDS, TEXAS

Nancy Simonian, MD
Former President and Chief Executive Officer
Syros Pharmaceuticals, Inc.
CAMBRIDGE, MASSACHUSETTS

Amoolya Singh, PhD
Chief Technology Officer
Delfi Diagnostics
PALO ALTO, CALIFORNIA
BALTIMORE, MARYLAND

Cynthia F. Sulzberger
WELLINGTON, FLORIDA

Judy C. Swanson
HILLSBOROUGH, CALIFORNIA

Peter Van Camp
Executive Chairman
Equinix, Inc.
REDWOOD CITY, CALIFORNIA

James A. Wells, PhD
Professor, Department of Pharmaceutical Chemistry
University of California, San Francisco
SAN FRANCISCO, CALIFORNIA

Yung S. Lie, PhD
President and Chief Executive Officer
Damon Runyon Cancer Research Foundation

DAMON RUNYON

BOARD OF DIRECTORS

EMERITUS MEMBERS

David Baltimore, PhD
President Emeritus
Judge Shirley Heufstedler Professor of Biology
California Institute of Technology
PASADENA, CALIFORNIA

Steven J. Burakoff, MD
Dean for Cancer Innovation
The Tisch Cancer Institute
Director Emeritus
The Tisch Cancer Institute
Chief, Division of Pediatric Hematology and Oncology
Lillian and Henry M. Stratton Professor of Cancer Medicine
Professor of Medicine
Professor of Oncological Sciences
Icahn School of Medicine at Mount Sinai
NEW YORK, NEW YORK

Leon G. Cooperman
Chairman and Chief Executive Officer
Omega Family Office
BOCA RATON, FLORIDA

Thomas J. Fahey, Jr., MD
Senior Vice President Emeritus
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Karen D. Gephardt
Founder & Managing Director
Fusion Partners Global LLC
NEW YORK, NEW YORK

Michael L. Gordon
NEW YORK, NEW YORK

Steve Hayden
Vice Chairman and Chief Creative Officer (retired)
Ogilvy & Mather Worldwide
NEW YORK, NEW YORK

Kenneth G. Langone
Chairman
Langone Family Office
NEW YORK, NEW YORK

Ronald Levy, MD
Robert K. and Helen K. Summy Professor
Stanford University School of Medicine
STANFORD, CALIFORNIA

Connie Lurie
ATHERTON, CALIFORNIA

I. George Miller, Jr., MD
John F. Enders Professor of Pediatrics
Professor of Epidemiology and of Molecular Biophysics & Biochemistry
Yale School of Medicine
NEW HAVEN, CONNECTICUT

John H. Myers
President (retired)
GE Asset Management
FAIRFIELD, CONNECTICUT

Katharine F. Plum
HOBE SOUND, FLORIDA

Samuel C. Silverstein, MD
Emeritus John C. Dalton Professor of Physiology & Cellular Biophysics
Professor of Medicine
Columbia University College of Physicians and Surgeons
NEW YORK, NEW YORK

Craig B. Thompson, MD
Former President & CEO
Memorial Sloan Kettering Cancer Center
Sloan Kettering Institute Member
NEW YORK, NEW YORK

Virginia Ueberroth
Chairman, The Ueberroth Family Foundation
CORONA DEL MAR, CALIFORNIA

Robert C. Wright
Senior Advisor, THL Capital
NEW YORK, NEW YORK

Robert C. Young, MD
Former Chancellor and President
Fox Chase Cancer Center
President
RCY Medicine
PHILADELPHIA, PENNSYLVANIA

BAY AREA COMMITTEE

CO-CHAIR

Gabrielle Layton, PhD*
PALO ALTO, CALIFORNIA

CO-CHAIR

Peter Van Camp*
Executive Chairman
Equinix, Inc.
REDWOOD CITY, CALIFORNIA

Levi A. Garraway, MD, PhD*
Executive Vice President
Head of Global Product Development
Chief Medical Officer
Genentech/Roche
SOUTH SAN FRANCISCO, CALIFORNIA

Noah Knauf*
General Partner
Bond Capital
SAN FRANCISCO, CALIFORNIA

Connie Lurie
ATHERTON, CALIFORNIA

Andrew S. Rachleff*
Executive Chairman
Wealthfront Inc.
PALO ALTO, CALIFORNIA

Isabel Rhee
LOS ALTOS, CALIFORNIA

Gordon M. Ringold, PhD
Chief Executive Officer
Quadriga Biosciences
LOS ALTOS, CALIFORNIA

Amoolya Singh, PhD*
Chief Technology Officer
Delfi Diagnostics
PALO ALTO, CALIFORNIA
BALTIMORE, MARYLAND

Judy C. Swanson*
HILLSBOROUGH, CALIFORNIA

James A. Wells, PhD*
Professor, Department of Pharmaceutical Chemistry
University of California, San Francisco
SAN FRANCISCO, CALIFORNIA

**Indicates member is also a Board Member*

AWARD PROGRAMS

In fiscal year 2024,
we awarded
$22,535,650 million
in new grants to
71 exceptional scientists.

DAMON RUNYON FELLOWSHIP AWARD

Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be mentored by established investigators in leading research laboratories across the country.

FOUR-YEAR AWARD: $300,000
plus up to $100,000 for medical school loan repayment

DAMON RUNYON QUANTITATIVE BIOLOGY FELLOWSHIP AWARD

Supports quantitative scientists (trained in fields such as mathematics, computer science, physics, engineering, or related) to pursue research careers in computational biology.

THREE-YEAR AWARD: $240,000
plus up to $100,000 for medical school loan repayment

DAMON RUNYON-DALE F. FREY AWARD FOR BREAKTHROUGH SCIENTISTS

Supports a select few Damon Runyon Fellows who have exceeded the Foundation's highest expectations. This additional investment in these exceptional individuals catapults their research careers and their impact on cancer.

TWO-YEAR AWARD: $100,000

DAMON RUNYON PHYSICIAN-SCIENTIST TRAINING AWARD

Supports and encourages outstanding recent medical school graduates to pursue cancer research careers by funding a protected research training experience under the guidance of a highly qualified and gifted mentor.

FOUR-YEAR AWARD: $460,000
plus up to $100,000 for medical school loan repayment

DAMON RUNYON CLINICAL INVESTIGATOR AWARD

Supports early career physician-scientists conducting patient-oriented research. This innovative program aims to increase the number of physicians who can seamlessly move between the laboratory and the patient's bedside in search of breakthrough treatments.

THREE-YEAR AWARD: $600,000
plus up to $100,000 for medical school loan repayment and the possibility of an additional $400,000 extension over two years

DAMON RUNYON-RACHLEFF INNOVATION AWARD

Supports the next generation of exceptionally creative thinkers with high-risk, high-reward ideas that have the potential to significantly impact our understanding of and approaches to the prevention, diagnosis, or treatment of cancer.

TWO-YEAR AWARD: $400,000
with the possibility of an additional $400,000 extension over two years

DAMON RUNYON-ST. JUDE PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD

In partnership with St. Jude Children's Research Hospital, this award provides funding to early career scientists conducting research with the potential to significantly impact the prevention, diagnosis, or treatment of one or more pediatric cancers.

FOUR-YEAR AWARD: $300,000
plus up to $100,000 for medical school loan repayment

DAMON RUNYON SCHOLARS PROGRAM FOR ADVANCING RESEARCH AND KNOWLEDGE (SPARK) AWARD

Provides outstanding recent college graduates with the potential to become scientific leaders with a financial stipend, intensive laboratory training, a network of mentors and peers, and other resources to support their next career steps.

ONE-YEAR POSTBACCALAUREATE PROGRAM: UP TO $61,000

DAMON RUNYON

FELLOWSHIP AWARD COMMITTEE

CHAIR

Kathryn A. O'Donnell, PhD
Associate Professor
Department of Molecular Biology
Co-Leader, Development and Cancer Program
Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
DALLAS, TEXAS

VICE CHAIR

Ken H. Cadwell, PhD
Professor of Medicine
Associate Director, Center for Molecular Studies in Digestive and Liver Diseases
Division of Gastroenterology and Hepatology
University of Pennsylvania Perelman School of Medicine
PHILADELPHIA, PENNSYLVANIA

OUTGOING CHAIR

Richard M. White, MD, PhD
Professor of Medicine
Nuffield Department of Medicine
Ludwig Cancer Research
University of Oxford
OXFORD, UNITED KINGDOM

David Bilder, PhD
Professor
Department of Molecular and Cell Biology
University of California, Berkeley
BERKELEY, CALIFORNIA

J. Javier Bravo-Cordero, PhD
Associate Professor
Division of Hematology and Oncology
Department of Medicine
The Tisch Cancer Institute
Advanced Bioimaging Center
Microscopy CORE
Icahn School of Medicine at Mount Sinai
NEW YORK, NEW YORK

Xinwei Cao, PhD
Associate Member
Developmental Neurobiology Department
Comprehensive Cancer Center
St. Jude Children's Research Hospital
MEMPHIS, TENNESSEE

Sreekanth Chalasani, PhD
Professor
Jesse and Caryl Philips Foundation Chair
Molecular Neurobiology Laboratory
Salk Institute for Biological Studies
LA JOLLA, CALIFORNIA

Jason M. Crawford, PhD
Professor
Departments of Chemistry and Microbial Pathogenesis
Yale University
WEST HAVEN, CONNECTICUT

Gianna E. Hammer, PhD
Associate Professor
Microbiology and Immunology
Burroughs Wellcome Fund Investigator
Pew Biomedical Scholar
University of Utah
SALT LAKE CITY, UTAH

Daniel F. Jarosz, PhD
Associate Professor
Department of Chemical and Systems Biology
Department of Developmental Biology
Stanford University School of Medicine
Member, Stanford Cancer Institute
STANFORD, CALIFORNIA

Katrin Karbstein, PhD
Ingram Professor of Cancer Research and Professor of Biochemistry
Vanderbilt University School of Medicine and Basic Sciences
Co-Leader of Cancer Cell Biology Program
Vanderbilt-Ingram Cancer Center
NASHVILLE, TENNESSEE

Martin McMahon, PhD
Cumming-Presidential Chair of Cancer Biology
Professor, Department of Dermatology
Senior Director for Preclinical Translation
Huntsman Cancer Institute
University of Utah Health School of Medicine
SALT LAKE CITY, UTAH

Raymond E. Moellering, PhD
Professor
Department of Chemistry
University of Chicago
CHICAGO, ILLINOIS

Alfonso Mondragón, PhD
Ethel and John Lindgren Professor
Director of the Structural Biology Facility
Department of Molecular Biosciences
Northwestern University
EVANSTON, ILLINOIS

Joshua C. Munger, PhD
Professor
Department of Biochemistry and Biophysics
Department of Microbiology and Immunology
Rochester Medical Center
School of Medicine and Dentistry
ROCHESTER, NEW YORK

Akinyemi I. Ojesina, MD, PhD
Assistant Professor
Department of Obstetrics and Gynecology
Medical College of Wisconsin
MILWAUKEE, WISCONSIN

Arun Radhakrishnan, PhD
Professor
Department of Molecular Genetics
University of Texas Southwestern Medical Center
DALLAS, TEXAS

Rajat Rohatgi, MD, PhD
Professor of Biochemistry and Medicine (Oncology)
Stanford University School of Medicine
STANFORD, CALIFORNIA

Carla Rothlin, PhD
Dorys McConnell Duberg Professor of Immunobiology and Pharmacology
Co-leader Cancer Immunology Program
Yale Cancer Center
Yale School of Medicine
NEW HAVEN, CONNECTICUT

Jared Rutter, PhD
Howard Hughes Medical Institute Investigator
Dee Glen and Ida Smith Endowed Chair for Cancer Research
Distinguished Professor of Biochemistry
University of Utah Health School of Medicine
SALT LAKE CITY, UTAH

Agnel Sfeir, PhD
Paine Webber Chair in Cancer Genetics
Member, Molecular Biology Program
Sloan Kettering Institute
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

David R. Sherwood, PhD
Jerry G. and Patricia Crawford Hubbard Professor and Associate Chair of Biology
Department of Biology
Duke University
DURHAM, NORTH CAROLINA

DAMON RUNYON

FELLOWSHIP AWARD

CALIFORNIA

California Institute of Technology

Bo Gu, PhD
Fraternal Order of Eagles Fellow
Understanding and engineering combinatorial gene regulation in mammalian cells with Michael B. Elowitz, PhD

Georgia R. Squyres, PhD
National Mah Jongg League Fellow
Spatiotemporal regulation of eDNA release in *Pseudomonas aeruginosa* biofilms with Dianne K. Newman, PhD

Gladstone Institutes

Ronghui Zhu, PhD
Connie and Bob Lurie Fellow
Mapping and modeling the human CD4+ T cell differentiation gene regulatory network with Alexander Marson, MD, PhD (Gladstone Institutes), and Jonathan K. Pritchard, PhD (Stanford University)

Salk Institute

Wen Mai Wong, PhD
Kenneth G. and Elaine A. Langone Fellow
Modulation of neuronal circuitry using sonogenetics with Sreekanth H. Chalasani, PhD

Stanford University

Felix C. Boos, PhD
Inter-organ communication of protein homeostasis stress responses in vertebrate aging with Anne Brunet, PhD

Laura Crowley, PhD*
HHMI Fellow
Identifying fibroblast stem cells in organ maintenance, repair, and cancer with Mark A. Krasnow, MD, PhD

Lauren E. Cote, PhD
Constructing one continuous digestive tract, cell by cell with Jessica L. Feldman, PhD

Brendan Floyd, PhD*
HHMI Fellow
Systematic characterization of lysosomal-targeting protein degradation with Carolyn R. Bertozzi, PhD

Lucia Ichino, PhD
HHMI Fellow
Mechanisms underlying cis-regulatory rewiring and chromatin reorganization during epithelial to mesenchymal transition with Joanna K. Wysocka, PhD

Seungsoo Kim, PhD
Transcription factor cooperation shaping TWIST1 multifunctionality across craniofacial development and cancer metastasis with Joanna K. Wysocka, PhD

Conor J. McClune, PhD
Resolving plant biosynthesis of therapeutic compounds by systematic perturbation, measurement, and metabolic phenotyping at single-cell scale with Elizabeth S. Sattely, PhD, and Polly M. Fordyce, PhD

David S. Roberts, PhD*
Connie and Bob Lurie Fellow
Defining the molecular landscape and native interactome of the Siglecsialoglycan axis in disease with Carolyn R. Bertozzi, PhD

Xianfeng Zeng, PhD*
Microbiome-cancer connection: From understanding to rational design with defined communities with Michael A. Fischbach, PhD

Stanford University School of Medicine

Layla J. Barkal, MD, PhD*§
Using commensal skin bacteria for potent, antigen-specific T cell therapy with Michael A. Fischbach, PhD

Debadrita Bhattacharya, PhD
Robert Black Fellow
Investigating molecular and cellular mechanisms of intra-tumoral heterogeneity in small-cell lung cancer with Julien Sage, PhD

Simon Sretenovic, PhD*
Connie and Bob Lurie Fellow
High-throughput precision genome editing for dissecting complex traits in yeast and human cell lines with Lars M. Steinmetz, PhD

Xiaowei Yan, PhD
Connie and Bob Lurie Fellow
Spatial organization and inheritance regulation of oncogenic extrachromosomal DNA (ecDNA) with Howard Y. Chang, MD, PhD

University of California, Berkeley

R. Camille Brewer, PhD*
HHMI Fellow
Defining how early-life microbial encounters sculpt the B cell repertoire and shape vaccine responses with Gregory M. Barton, PhD

Ben F. Brian, PhD
HHMI Fellow
Mechanisms and consequences of microbiota-directed immune responses with Gregory M. Barton, PhD

Gabriel Cavin-Meza, PhD
Merck Fellow
Leveraging polyploid *Xenopus* to probe spindle adaptation to increases in genome size with Rebecca Heald, PhD

Timothy J. Eisen, PhD
David Ryland Fellow
Mechanistic dissection of Tec kinases in immune-cell signaling with Jay Groves, PhD (University of California, Berkeley), and John Kuriyan, PhD (Vanderbilt University)

Yoshiki Sakai, PhD*
Rhee Family Fellow
How do tumors evade cell extrusion? with David Bilder, PhD

Joshua B. Sheetz, PhD
HHMI Fellow
Mitochondrial ubiquitylation mechanisms to exploit metabolic vulnerabilities in cancer with Michael Rape, PhD

Akanksha Thawani, PhD
Merck Fellow
Targeted genetic supplementation by harnessing transposable elements with Eva Nogales, PhD, and Kathleen Collins, PhD

University of California, Los Angeles

Yajing Gao, PhD
The Mark Foundation for Cancer Research Fellow
Characterize the role of non-vesicular cholesterol transport in CD8+ T cell function with Peter Tontonoz, MD, PhD

University of California, San Diego

Jinchun Wu, PhD*
Marion Abbe Fellow
Identifying cytoplasmic nucleases that shatter micronucleated chromosomes with Don W. Cleveland, PhD

University of California, San Francisco

Sagar Bhattacharya, PhD*
Connie and Bob Lurie Fellow
De novo design of protease-activated anticancer proteins with William F. DeGrado, PhD

Fangyu Liu, PhD
Discovery of novel ligands that treat metabolic disorders with Brian K. Shoichet, PhD

Tadashi Manabe, MD, PhD
Connie and Bob Lurie Fellow
Characterization of oncogenic kinase signaling by membrane-less cytoplasmic protein granules with Trever G. Bivona, MD, PhD

Fanglue Peng, PhD
Connie and Bob Lurie Fellow
Humanize CXCL13 expression in mouse to understand lymphoid neogenesis in cancer with Jason G. Cyster, PhD

Erron W. Titus, MD, PhD§
Connie and Bob Lurie Fellow
Engineered cellular fusogens for novel immune effector functions with Matthew F. Krummel, PhD

Shaohua Zhang, PhD*
Timmerman Traverse Fellow
Preventing tumor evasion of CAR T killing: engineering adhesion molecules to enhance cell immunotherapy with Wendell A. Lim, PhD

Qinheng Zheng, PhD
Connie and Bob Lurie Fellow
Drugging K-Ras(G12D) with targeted covalent inhibitors with Kevan M. Shokat, PhD

COLORADO

University of Colorado Boulder

Edward M. C. Courvan, PhD
HHMI Fellow
Functional analysis of post-transcriptional RNA regulation in hypoxic macrophages with Roy R. Parker, PhD

Nicole M. Hoitsma, PhD
HHMI Fellow
Chromatin remodeler SMARCAD1 in DNA repair with Karolin Luger, PhD

Dylan M. Parker, PhD
HHMI Fellow
Stress granule regulators and their roles in cancer progression with Roy R. Parker, PhD

CONNECTICUT

Yale University

Hui (Vivian) Chiu, PhD
HHMI Fellow
The neuroimmune basis of fatigue with Ruslan Medzhitov, PhD

Jung-Shen Benny Tai, PhD
From form to function: Cell shape, cell ordering, and gene regulation in bacterial biofilm with Jing Yan, PhD (Yale University), and Christopher Waters, PhD (Michigan State University)

ILLINOIS

Northwestern University

John Devany, PhD*
Bakewell Foundation Fellow
Engineering next-generation T cell therapies by learning from cancer mutations with Jaehyuk Choi, MD, PhD

MARYLAND

National Institutes of Health

Claudia A. Rivera Cifuentes, PhD
Lorraine W. Egan Fellow
Endogenous retroviruses modulation of intestinal immune homeostasis and tumor development with Yasmine Belkaid, PhD (Institut Pasteur), and Michail Lionakis, MD, ScD (National Institutes of Health)

The Johns Hopkins University School of Medicine

Marco A. Catipovic, PhD
In vitro reconstitution of ribosome collision dependent signaling with Rachel Green, PhD

Cayla E. Jewett, PhD
Merck Fellow
Mechanisms of centriole number control in multiciliated cells with Andrew J. Holland, PhD

MASSACHUSETTS

Boston Children's Hospital

Shreoshi Sengupta, PhD*
Deborah J. Coleman Fellow
Decoding cell-cell interactions aiding angiogenesis and immune evasion in early-stage lung cancer with Carla F. Kim, PhD

Boston University

Heidi E. Klumpe, PhD
Merck Fellow
The design principles of stable aggregation with Ahmad S. Khalil, PhD, and Mary Dunlop, PhD

Brigham and Women's Hospital

Xiphias Ge Zhu, PhD
HHMI Fellow
Charting the tumor antigen landscape of breast cancer with Stephen J. Elledge, PhD

Jordan B. Jastrab MD, PhD*§
Robert Black Fellow
Molecular mechanisms of inflammasome activation by intraphagosomal bacteria with Jonathan C. Kagan, PhD

Broad Institute

Chaiheon Lee, PhD*
Suzanne and Bob Wright Fellow
Development of haptenizing chimeras for neoantigen generation with Amit Choudhary, PhD

Wendy Xueyi Wang, PhD
National Mah Jongg League Fellow
Dissecting the molecular identity and contents of neuronal synapses using spatially resolved RNA sequencing with Xiao Wang, PhD (Broad Institute), and Jia Liu, PhD (Harvard University)

Dana-Farber Cancer Institute

Kheewoong Baek, PhD*
Expansion of the glueable and degradable targets of IMiD-CRBN with Eric S. Fischer, PhD

Anders B. Dohlman, PhD
Meghan E. Raveis Fellow
Identifying the genomic basis for *Fusobacterium nucleatum*'s colonization of colorectal cancers with Matthew L. Meyerson, MD, PhD

Archana Krishnamoorthy, PhD
HHMI Fellow
Mechanisms of chromosome fragmentation generating chromothripsis with David S. Pellman, MD (Dana-Farber Cancer Institute), and Johannes Walter, PhD (Harvard Medical School)

David M. Walter, PhD
Identifying the selective mechanism behind U2AF1 mutations in lung adeno-carcinoma with Matthew L. Meyerson, MD, PhD

Harvard Medical School

Hannah A. Grunwald, PhD
Lallage Feazel Wall Fellow
Unraveling the role of molecular capacitors that obscure cryptic genetic variants in fish with Clifford J. Tabin, PhD

Xin Gu, PhD
National Mah Jongg League Fellow
Characterization of a novel pathway regulating the protein degradation of immediate-early genes with Michael E. Greenberg, PhD

Brooke D. Huisman, PhD*
National Mah Jongg League Fellow
Elucidating the lineage relationships of thymic mimetic cells with Diane Mathis, PhD, and Christophe Benoist, MD, PhD

Manuel Osorio Valeriano, PhD
Philip O'Bryan Montgomery, Jr., MD, Fellow
Molecular and structural basis of gene expression regulation by the nucleosome remodeling and deacetylase (NuRD) complex in human cancer with Lucas Farnung, PhD, and Danesh Moazed, PhD

Rocío D. M. Saavedra-Peña, PhD*
HHMI Fellow
Probing sensory pathways in gut mechanosensation with Stephen D. Liberles, PhD

James C. Taggart, PhD*
Mechanistic interrogation of robustness and vulnerability in a bacterial essential gene network with Allon M. Klein, PhD, and Johan Paulsson, PhD

Harvard T.H. Chan School of Public Health

Madi Y. Cissé, PhD
Merck Fellow
Integration on oncogenic signaling and nutrient sensing by mTOR in tumors with Brendan D. Manning, PhD

Harvard University

Alon Chappleboim, PhD
Uncovering signaling mechanisms in somitogenesis through high-throughput genetic screens in robust human organoids with Sharad Ramanathan, PhD

Rongxin Fang, PhD
Genome-scale imaging of enhancer-promoter interactions in cancer at single cell resolution with Xiaowei Zhuang, PhD

Massachusetts General Hospital

Charles H. Adelmann, PhD
Systematic exploration of the organellar and cellular requirements of pigmentation with David E. Fisher, MD, PhD

Stefan Niekamp, PhD
Understanding the switch: Competition between chromatin remodeler and polycomb repressive complexes with Robert E. Kingston, PhD

Sangwoo Park, PhD*
Merck Fellow
Engineering novel CAR T cells targeting cancer glycocalyx barrier with Marcela V. Maus, MD, PhD

Massachusetts Institute of Technology

Fangtao Chi, PhD
Understanding how ketone body metabolites influence intestinal stemness, immune responses and tumorigenesis with Ömer H. Yilmaz, MD, PhD

Isabella Fraschilla, PhD
Merck Fellow
Examining bacteria as a source of tumor antigens with Tyler E. Jacks, PhD

J. Scott P. McCain, PhD
Estimating growth rates and fluxes using gene expression: Theory and applications with Gene-Wei Li, PhD

Senén D. Mendoza, PhD
HHMI Fellow
Discovery and characterization of bacterial immunity against RNA phages with Michael T. Laub, PhD

Expery O. Omollo, PhD*
Robert A. Swanson Family Fellow
Elucidating what determines the strength of bacterial transcription terminators with Gene-Wei Li, PhD

Ian J. Roney, PhD*
HHMI Fellow
Discovery and characterization of bacteriophage effectors of bacterial immune systems with Michael T. Laub, PhD

Patrick J. Woida, PhD
Functional dissection of the bacterial-host interface during cell-to-cell spread with Rebecca Lamason, PhD

Whitehead Institute for Biomedical Research

Henry R. Kilgore, PhD
Subcellular pharmacokinetics with Richard A. Young, PhD

Ryan Y. Muller, PhD
HHMI Fellow
Elucidating PABPC1 sequence preferences and determining how these preferences shape gene regulation with David P. Bartel, PhD

Pu Zheng, PhD
Fayez Sarofim Fellow
An integrated imaging- and sequencing-based spatial-omic method to study tumor evolution with Jonathan S. Weissman, PhD

MICHIGAN

Van Andel Institute

McLane Watson, PhD
Understanding CD8 T cell epigenetic changes fueled by S-adenosylmethionine metabolism for improved adoptive cell therapy with Russell G. Jones, PhD

MINNESOTA

University of Minnesota

Nicholas N. Jarjour, PhD
Antigen-independent proliferation of tissue-resident memory T cells and therapeutic applications with Stephen C. Jameson, PhD

NEW JERSEY

Princeton University

Grace E. Johnson, PhD
HHMI Fellow
Defining quorum-sensing signaling patterns and their effects on gene expression and morphology in *V. cholerae* biofilms at the single-cell and community levels with Bonnie L. Bassler, PhD

Aaron E. Lin, PhD
Walter Isaacson Fellow
Contact tracing within an organism: developing a genome editing platform to record the history of virus-infected and transformed cells with Alexander Ploss, PhD, and Brittany Adamson, PhD

Titas Sengupta, PhD
Rebecca Ridley Kry Fellow
Investigating bacterial small RNA-mediated regulation of host behavior with Coleen T. Murphy, PhD

Cheng Yang, PhD*
Chemoproteomic platforms for deciphering and drugging redox regulation between methionine and methionine sulfoxide in pancreatic cancer with Christopher J. Chang, PhD

Juner Zhang, PhD
The role of histone H2A.Z monoaminylation in transcription regulation with Tom W. Muir, PhD

NEW YORK

Columbia University

Mingjian Du, PhD
HHMI Fellow
The gut-brain axis mediating overnutrition with Charles S. Zuker, PhD

James Swann, VetMB, DPhil
Emergency myelopoiesis pathways as common drivers of clonal dominance and disease progression in acute myeloid leukemia with Emmanuelle Passegué, PhD

Memorial Sloan Kettering Cancer Center

Rico C. Ardy, PhD
Robert Black Fellow
An atlas of fibroblast cell states in health and disease through functional genomics with Thomas Norman, PhD

Antonio Cuevas-Navarro, PhD*
Berger Foundation Fellow
Elucidating mechanisms that reverse the detrimental effect of RAS mutations in cancer with Piro Lito, MD, PhD

Michael V. Gormally, MD, PhD*§
Dennis and Marsha Dammerman Fellow
Immunologic targeting of "undruggable" TP53 hotspot mutations through T cell receptor gene therapy with Christopher A. Klebanoff, MD, and Michael F. Berger, PhD

Tamar Kavlashvili, PhD*
Timmerman Traverse Fellow
Developing tools to mechanistically investigate the mtDNA 'common deletion' with Agnel Sfeir, PhD

Nalin Ratnayeke, PhD*
HHMI Fellow
Dissecting heterogeneous cellular responses to oncogenic KRAS inhibition in pancreatic adenocarcinoma with Scott W. Lowe, PhD

Pu Zhang, PhD*
Understanding the role of R-loops in cancer at the single cell level with Omar Abdel-Wahab, MD

Zeda Zhang, PhD
HHMI Fellow
Decode the senescent cell surface *in vivo* and develop cell therapies for senescence-related diseases with Scott W. Lowe, PhD

The Rockefeller University

Catherine A. Freije, PhD
Berger Foundation Fellow
Investigating the role of fitness and host pressure in shaping hepatitis B diversity with Charles M. Rice, PhD

Wenzhi Song, PhD*
HHMI Fellow
Neuroimmune: cancer stem cell interactions in the tumor microenvironment with Elaine V. Fuchs, PhD

NORTH CAROLINA

Duke University

Elizabeth R. Hughes, PhD
Robert Black Fellow
Mechanisms of microbial modulation of cancer immunotherapy with Raphael H. Valdivia, PhD

PENNSYLVANIA

University of Pennsylvania

Nicholas P. Lesner, PhD
Hepatic urea cycle function in NASH-induced HCC progression with M. Celeste Simon, PhD

Rebecca S. Moore, PhD
HHMI Fellow
Investigation of the role of peripheral secreted molecules on sleep and circadian rhythms with Amita Sehgal, PhD

Christopher Noetzel, PhD
How do eukaryotic cells count cell cycles? Intrinsic regulation of quantized asexual replication cycles and commitment to sexual differentiation in the protozoan parasite *Cryptosporidium parvum* with Boris Striepen, PhD

Catherine Triandafillou, PhD
National Mah Jongg League Fellow
Intrinsic and extrinsic drivers of heterogeneous drug resistance in cancer with Arjun Raj, PhD

TENNESSEE

Vanderbilt University Medical Center

Sarah L. Price, PhD*
Merck Fellow
Targeting *Clostridioides difficile* biofilm dynamics to combat recurrent infections with Eric P. Skaar, PhD

WASHINGTON

Fred Hutchinson Cancer Center

Ching-Ho Chang, PhD
Genetic conflicts shape protamine evolution with Harmit S. Malik, PhD

Edie I. Crosse, PhD
Illini 4000 Fellow
Precision therapeutics for hematologic malignancies with splicing factor mutations with Robert Bradley, PhD

Grant A. King, PhD
HHMI Fellow
How do host cells engage with extrachromosomal DNA? with Harmit S. Malik, PhD

Siqi Li, PhD
The Mark Foundation for Cancer Research Fellow
Deciphering clonal competition between oncogenic mutant and normal cells and its effect on cancer initiation with Slobodan Beronja, PhD

University of Washington

Wei (Will) Chen, PhD
Decoding the transcription code: *de novo* protein design for precise gene regulation with David Baker, PhD

Jean-Benoît Lalanne, PhD
At-scale dissection of developmental enhancers with single-cell reporters with Jay A. Shendure, MD, PhD

Erik Van Dis, PhD
Robert Black Fellow
Investigating innate immune activation in the autoimmune pancreas with Daniel B. Stetson, PhD

CANADA

University of Calgary

Marie R. Siwicki, PhD
Dale F. and Betty Ann Frey Fellow
Investigating neutrophil functional heterogeneity in wound healing and cancer with Paul Kubes, PhD

**Initial Year*
§Physician-Scientists

DAMON RUNYON

QUANTITATIVE BIOLOGY FELLOWSHIP AWARD COMMITTEE

CHAIR

Todd R. Golub, MD
Director and Founding Core Institute Member
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Professor of Pediatrics
Harvard Medical School
CAMBRIDGE, MASSACHUSETTS

Gaudenz Danuser, PhD
Patrick E. Haggerty Distinguished Chair in Basic Biomedical Science
Lyda Hill Department of Bioinformatics and Department of Cell Biology
CPRIT Scholar in Cancer Research
University of Texas Southwestern Medical Center
DALLAS, TEXAS

Anshul Kundaje, PhD
Associate Professor of Genetics and Computer Science
Stanford University
STANFORD, CALIFORNIA

Han Liang, PhD, FAAS
AAAS Fellow
Barnhart Family Distinguished Professor in Targeted Therapies
Professor and Deputy Chair, Department of Bioinformatics and Computational Biology
Professor, Department of Systems Biology
University of Texas MD Anderson Cancer Center
HOUSTON, TEXAS

Dana Pe'er, PhD
Howard Hughes Medical Institute Investigator
Chair, Computational and Systems Biology Program
Alan and Sandra Gerry Endowed Chair
Sloan Kettering Institute
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Amoolya Singh, PhD
Chief Technology Officer
Delfi Diagnostics
PALO ALTO, CALIFORNIA
BALTIMORE, MARYLAND

Cole Trapnell, PhD
Associate Professor
Department of Genome Sciences
University of Washington
SEATTLE, WASHINGTON

Caroline Uhler, PhD
Professor
Department of Electrical Engineering and Computer Science
Institute for Data, Systems, and Society
Massachusetts Institute of Technology
Core Institute Member
Co-Director, Eric and Wendy Schmidt Center
Broad Institute of MIT and Harvard
CAMBRIDGE, MASSACHUSETTS

Eliezer M. Van Allen, MD
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Population Sciences
Dana-Farber Cancer Institute
Member
Broad Institute of MIT and Harvard
BOSTON, MASSACHUSETTS

DAMON RUNYON

QUANTITATIVE BIOLOGY FELLOWSHIP AWARD

CALIFORNIA

Stanford University

Jakob Wirbel, PhD*
Microbial genome variation in hematopoietic stem-cell transplantation patients with Ami Bhatt, MD, PhD, and Mike Bassik, PhD

University of California, San Francisco

Youngmu (Nick) Shin, PhD
Exploring phase condensation as a general mechanism for organizing cell-cell communication assemblies with Wendell A. Lim, PhD (University of California, San Francisco), and Rohit V. Pappu, PhD (Washington University in St. Louis)

MASSACHUSETTS

Dana-Farber Cancer Institute

Ahmed Roman, PhD*
Leslie Cohen Seidman Quantitative Biology Fellow
Signal bottleneck theory for dissecting gene interactions in pancreatic cancer with Eliezer M. Van Allen, MD, and Andrew J. Aguirre, MD, PhD

NEW JERSEY

Princeton University

Cong Ma, PhD
Modeling spatial organization and interactions among genetic and epigenetic states across cancer types with Benjamin Raphael, PhD (Princeton University), and Li Ding, PhD (Washington University in St. Louis)

Jeremy A. Owen, PhD*
The biophysics of substrate recognition in chromatin remodeling with Tom W. Muir, PhD, and Ned S. Wingreen, PhD

Carolina Trenado-Yuste, PhD
Screening migratory modes and drug delivery schedules in 3D spheroids of triple-negative breast cancer cells with Celeste M. Nelson, PhD, and Ned S. Wingreen, PhD

NEW YORK

Memorial Sloan Kettering Cancer Center

Sukrit Singh, PhD
Physics-driven prediction of drug-resistant clinical mutations to improve precision oncology with John D. Chodera, PhD (Memorial Sloan Kettering Cancer Center), and Markus A. Seeliger, PhD (Stony Brook University)

New York Genome Center

Isabella N. Grabski, PhD*
Kenneth G. Langone Quantitative Biology Fellow
A probabilistic framework for deconvolving causal mechanisms of cancer therapeutics with David A. Knowles, PhD, and Rahul Satija, PhD

WASHINGTON

Fred Hutchinson Cancer Center

Yapeng Su, PhD
Quantitative analysis to elucidate spatial-temporal heterogeneity of therapeutic T cell dysfunction mechanisms in the context of adoptive cell therapy against pancreatic cancer with Philip D. Greenberg, MD, and Raphael Gottardo, PhD

University of Washington

Nicholas C. Lammers, PhD
A computational platform for predicting whole-embryo morphologies from single-cell transcriptomes with Cole Trapnell, PhD, and David Kimelman, PhD

**Initial Year*

DAMON RUNYON

DALE F. FREY AWARD FOR BREAKTHROUGH SCIENTISTS

Zibo Chen, PhD
Protein-based molecular programming for cancer immunotherapy at Westlake University, Hangzhou, China

Junhong Choi, PhD
Uncovering cell-fate decision via molecular recording at Memorial Sloan Kettering Cancer Center, New York

Rachel S. Greenberg, PhD
The function of interoceptive circuits in reproduction and cancer at Harvard Medical School, Boston

Jingchuan Luo, PhD
Decoding the role of localized translation in normal physiology and cancer metastasis at Whitehead Institute for Biomedical Research, Cambridge

Mark R. Sullivan, PhD
Identifying determinants of pathogenesis and drug resistance in opportunistic lung infection at Harvard T.H. Chan School of Public Health, Boston

Julia Su Zhou Li, PhD
Uncovering the link between repetitive DNA, genomic instability, and tumor viruses at Boston Children's Hospital, Boston

DAMON RUNYON

PHYSICIAN-SCIENTIST TRAINING AWARD COMMITTEE

CHAIR

William G. Kaelin, Jr., MD
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute and Harvard Medical School
Howard Hughes Medical Institute Investigator
BOSTON, MASSACHUSETTS

David P. Carbone, MD, PhD
Barbara J. Bonner Chair in Lung Cancer Research
Director, James Thoracic Center
Professor, Division of Medical Oncology
Comprehensive Cancer Center
The Ohio State University
COLUMBUS, OHIO

Lucy A. Godley, MD, PhD
Jeffrey and Marianne Silver Family Professor of Oncology
Director, Silver Family Blood Cancer Institute
Clinical Director of Cancer Genetics
Robert H. Lurie Comprehensive Cancer Center
Division of Hematology/Oncology
Northwestern University
CHICAGO, ILLINOIS

Nada Jabado, MD, PhD
Professor, Pediatrics and Human Genetics
McGill University
Physician, Division of Hematology and Oncology
Montreal Children's Hospital
MONTREAL, CANADA

David R. Piwnica-Worms, MD, PhD
Professor and Chair, Cancer Systems Imaging
Executive Director, Quantitative Imaging Analysis Core
Gerald Dewey Dodd, Jr., Endowed Distinguished Chair in Diagnostic Imaging
Division of Diagnostic Imaging
University of Texas MD Anderson Cancer Center
HOUSTON, TEXAS

Jean Y. Tang, MD, PhD
Professor of Dermatology
Member, Stanford Cancer Institute
Stanford University School of Medicine
REDWOOD, CALIFORNIA

Matthew G. Vander Heiden, MD, PhD
Director, Koch Institute for Integrative Cancer Research at MIT
Lester Wolfe (1919) Professor of Molecular Biology
Professor of Biology
Member, MIT Center for Precision Cancer Medicine
Member, Ludwig Center at MIT
Member, Broad Institute of MIT and Harvard
CAMBRIDGE, MASSACHUSETTS

DAMON RUNYON

PHYSICIAN-SCIENTIST TRAINING AWARD

CALIFORNIA

Caitlin F. Bell, MD
Smooth muscle cell plasticity in the tumor microenvironment: another parallel between atherosclerosis and cancer with Nicholas J. Leeper, MD, and Irving L. Weissman, MD, Stanford University School of Medicine, Stanford

MASSACHUSETTS

Wallace A. Bourgeois, MD
Characterizing mechanisms of resistance to Menin inhibitors in KMT2A-rearranged and NPM1-mutant AML with Scott A. Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston

Albert E. Kim, MD
William G. Kaelin, Jr., MD, Physician-Scientist
Using liquid biopsy and MRI to non-invasively identify therapeutic targets for brain metastases with Elizabeth R. Gerstner, MD, Massachusetts General Hospital, Boston

(Peter) Geon Kim, MD
Elucidating the mechanisms of inflammation in clonal hematopoiesis with Benjamin L. Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston

Vignesh Shanmugam, MD*
Uncovering microenvironmental dependencies in follicular lymphoma with Todd R. Golub, MD, Brigham and Women's Hospital, Boston

Mounica Vallurupalli, MD
David M. Livingston, MD, Physician-Scientist
Defining the mechanistic implications of SF3B1 mutations in MDS with Todd R. Golub, MD, Dana-Farber Cancer Institute, Boston

Nina Weichert-Leahey, MD
Elucidating the role of KAT6A and KAT6B in the epigenetic reprogramming of neuroblastoma to enforce neuronal differentiation with A. Thomas Look, MD, Dana-Farber Cancer Institute, Boston

Rebecca L. Zon, MD*
The Mark Foundation for Cancer Research Physician-Scientist
Defining the mechanism of thrombosis in patients with multiple myeloma with Benjamin L. Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston

NEW YORK

Nicole M. Cruz, MD
The Mark Foundation for Cancer Research Physician-Scientist
Understanding the role of KMT2D in MLL-AF9 acute myeloid leukemia with Robert G. Roeder, PhD, The Rockefeller University, New York

Xiaoli Mi, MD*
Origin and evolution of long-lived CAR T cells in patients with hermatologic malignancies with Omar Abdel-Wahab, MD, and Dan A. Landau, MD, PhD, Memorial Sloan Kettering Cancer Center, New York

Mira A. Patel, MD
Molecular mechanisms of human APOE-mediated myeloid cell modulation in cancer with Sohail F. Tavazoie, MD, PhD, The Rockefeller University, New York

PENNSYLVANIA

Rahul Bhansali, MD*
Investigating chromatin architectural dynamics mediated by LDB1 in T-cell acute lymphoblastic leukemia with Gerd A. Blobel, MD, PhD, University of Pennsylvania, Philadelphia

**Initial Year*

DAMON RUNYON

CLINICAL INVESTIGATOR AWARD COMMITTEE

CHAIR

Ralph J. DeBerardinis, MD, PhD
Howard Hughes Medical Institute Investigator
Professor, Children's Research Institute
Chief, Division of Pediatric Genetics and Metabolism
Director, Genetic and Metabolic Disease Program
Sowell Family Scholar in Medical Research
Joel B. Steinberg, MD Distinguished Chair in Pediatrics
University of Texas Southwestern Medical Center
DALLAS, TEXAS

VICE CHAIR

Mignon L. Loh, MD
Chief, Division of Pediatric Hematology, Oncology, Bone Marrow Transplant, and Cellular Therapies
Seattle Children's Hospital
Director, Ben Towne Center for Childhood Cancer Research
Seattle Children's Research Institute
Professor of Pediatrics, Hematology-Oncology
University of Washington
Head, Pediatric Oncology Section
Fred Hutchinson Cancer Center
SEATTLE, WASHINGTON

Scott A. Armstrong, MD, PhD
Senior Vice President for Drug Discovery and Chief Research Strategy Officer
President, Dana-Farber/ Boston Children's Cancer and Blood Disorders Center
Chair, Department of Pediatric Oncology
Dana-Farber Cancer Institute
Associate Chief, Division of Hematology/Oncology
Boston Children's Hospital
David G. Nathan Professor of Pediatrics
Harvard Medical School
BOSTON, MASSACHUSETTS

J. Robert Beck, MD
Professor Emeritus
H.O. West and J.R. Wike Chair in Cancer Research
Fox Chase Cancer Center
PHILADELPHIA, PENNSYLVANIA

Howard A. Fine, MD
Director, Brain Tumor Center
Associate Director, Translational Research
Sandra and Edward Meyer Cancer Center
Louis and Gertrude Feil Professor of Medicine
Chief, Division of Neuro-Oncology
New York-Presbyterian/ Weill Cornell Medicine
NEW YORK, NEW YORK

Daniel F. Hayes, MD, FASCO, FACP
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan Rogel Cancer Center
ANN ARBOR, MICHIGAN

Dan A. Laheru, MD
Professor of Oncology
Co-Director, Skip Viragh Center for Pancreas Cancer
Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
BALTIMORE, MARYLAND

Ross L. Levine, MD
Senior Vice President, Translational Research
Memorial Hospital
Laurence Joseph Dineen Chair in Leukemia Research
Department of Medicine
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Daniel C. Link, MD
Alan and Edith Wolff Endowed Professor
Chief, Division of Oncology
Deputy Director, Alvin J. Siteman Cancer Center
Washington University School of Medicine
ST. LOUIS, MISSOURI

Ramon E. Parsons, MD, PhD
Director, Tisch Cancer Institute
Dean for Cancer Research, Icahn School of Medicine at Mount Sinai
Ward-Coleman Chair in Cancer Research
Director, Mount Sinai Cancer Center and Mount Sinai Health System
Professor and Chair, Oncological Sciences
Icahn School of Medicine at Mount Sinai
NEW YORK, NEW YORK

Ann Partridge, MD, MPH
Interim Chair, Department of Medical Oncology
Founder and Director, Program for Young Women with Breast Cancer
Director, Adult Survivorship Program
Eric P. Winder, MD, Chair in Breast Cancer Research
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
BOSTON, MASSACHUSETTS

Katerina Politi, PhD
Joseph A. and Lucille K. Madri Professor of Pathology
Co-Leader, Cancer Signaling Networks Research Program
Scientific Director, Center for Thoracic Cancers
Yale Cancer Center and Yale School of Medicine
NEW HAVEN, CONNECTICUT

Vered Stearns, MD, FASCO
Director for Translational Breast Cancer Research
Hematology and Medical Oncology
Associate Director for Clinical Services
Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine
NEW YORK, NEW YORK

Jedd D. Wolchok, MD, PhD, FASCO, FAACR
Meyer Director
Sandra and Edward Meyer Cancer Center
Professor of Medicine
Weill Cornell Medicine
NEW YORK, NEW YORK

Kwok-Kin Wong, MD, PhD
Anne Murnick Cogan and David H. Cogan Professor of Oncology
Department of Medicine
NYU Grossman School of Medicine
Director, Division of Hematology and Medical Oncology
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
NEW YORK, NEW YORK

Founding Member

Richard J. O'Reilly, MD
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

DAMON RUNYON

CLINICAL INVESTIGATOR AWARD

CALIFORNIA

Steven M. Corsello, MD*
Leslie Cohen Seidman Clinical Investigator
Targeting intrinsic immune signaling in pancreatic cancer with small molecule therapeutics with Nathanael S. Gray, PhD, and Ronald Levy, MD, Stanford University School of Medicine, Stanford

Daniel J. Delitto, MD, PhD
Pathogen sensing in fibroblasts restrains antitumor immunity in pancreatic cancer with Michael T. Longaker, MD, DSc, Stanford University, Stanford

Melody Smith, MD
Regulatory mechanisms of the intestinal microbiome on chimeric antigen receptor T cells with Robert S. Negrin, MD, Stanford University, Stanford

MARYLAND

Fyza Y. Shaikh, MD, PhD
Defining microbiome stability and longitudinal shifts as biomarkers of tumor response to immune checkpoint inhibitors across multiple malignancies with Cynthia L. Sears, MD, and Drew M. Pardoll, MD, PhD, The Johns Hopkins University School of Medicine, Baltimore

MASSACHUSETTS

Sylvan C. Baca, MD, PhD
Epigenetic drivers of resistance to novel therapies for bladder and kidney cancer with Toni K. Choueiri, MD, Dana-Farber Cancer Institute, Boston

Megan Insco, MD, PhD*
Targeting cancer-associated aberrant RNA to treat metastatic melanoma with F. Stephen Hodi, MD, Dana-Farber Cancer Institute, Boston

Erin M. Parry, MD, PhD*
Defining follicular lymphoma transformation: molecular basis, detection and therapeutic vulnerabilities with Margaret A. Shipp, MD, Dana-Farber Cancer Institute, Boston

Lachelle D. Weeks, MD, PhD*
Timmerman Traverse Clinical Investigator
Predicting leukemia risk from peripheral blood smears with Benjamin L. Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston

MICHIGAN

John R. Prensner, MD, PhD*
Ben and Catherine Ivy Foundation Clinical Investigator
Targeting TRIM29 to reverse immune checkpoint inhibitor resistance in bladder cancer with Joshi J. Alumkal, MD, University of Michigan, Ann Arbor

MISSOURI

Mary Mullen, MD*
COPS5 as a novel therapeutic target in platinum-resistant ovarian cancer with Dineo Khabele, MD, and Nima Mosammaparast, MD, PhD, Washington University, St. Louis

Nathan Singh, MD
Bakewell Foundation Clinical Investigator
Tailored cellular engineering to overcome costimulation-driven CAR T cell dysfunction with John F. DiPersio, MD, PhD, Washington University, St. Louis

NEW YORK

Andrew L. Ji, MD
Dissecting spatial crosstalk in squamous cell carcinoma arising in organ transplant recipients with Miriam Merad, MD, PhD, Icahn School of Medicine at Mount Sinai, New York

Santosha A. Vardhana, MD, PhD
Gordon Family Clinical Investigator
Overcoming metabolic suppression of anti-tumor immunity in gastric cancer with Charles L. Sawyers, MD, Memorial Sloan Kettering Cancer Center, New York

Aaron D. Viny, MD
Damon Runyon-Doris Duke Clinical Investigator
Epigenetic coupling of DNA methylation and chromatin structure on leukemic transformation and therapeutic responsewith Emmanuelle Passegué, PhD, and Joseph G. Jurcic, MD, Columbia University, New York

PENNSYLVANIA

Benjamin A. Nacev, MD, PhD
Understanding and targeting chromatin reorganization in ATRX deficient sarcomas with Jeremy N. Rich, MD, University of Pittsburgh, Pittsburgh

TEXAS

Pavan Bachireddy, MD
Immune evasive circuits that define MRD progression in myelodysplastic syndrome with Jeffrey J. Molldrem, MD, University of Texas MD Anderson Cancer Center, Houston

Xiuning Le, MD, PhD
Structure- and lineage-based classification and targeting of resistance in EGFR-mutant NSCLC with John V. Heymach, MD, PhD, University of Texas MD Anderson Cancer Center, Houston

**Initial Year*

DAMON RUNYON

CLINICAL INVESTIGATOR CONTINUATION GRANTS

CALIFORNIA

David Y. Oh, MD, PhD
Co-receptors modulating anti-tumor activity of human cytotoxic CD4+ effector cells with Lawrence Fong, MD (Fred Hutchinson Cancer Center), University of California, San Francisco

MICHIGAN

Phillip L. Palmbos, MD, PhD
Targeting TRIM29 to reverse immune checkpoint inhibitor resistance in bladder cancer with Joshi J. Alumkal, MD, University of Michigan, Ann Arbor

MISSOURI

Kelly L. Bolton, MD, PhD
The use of enasidenib in IDH2-mutated clonal cytopenia of undetermined significance with Matthew J. Walter, MD, and Eytan M. Stein, MD, Washington University School of Medicine, St. Louis

PENNSYLVANIA

Alexander C. Huang, MD
Shared antigen and neoantigen-specific T cells in checkpoint blockade efficacy and toxicity with Gerald P. Linette, MD, PhD, University of Pennsylvania, Philadelphia

DAMON RUNYON-RACHLEFF

INNOVATION AWARD COMMITTEE

CO-CHAIR

Julien Sage, PhD
Elaine and John Chambers Professor of Pediatric Cancer
Professor of Genetics
Stanford University School of Medicine
STANFORD, CALIFORNIA

CO-CHAIR

Julie K. Schwarz, MD, PhD
Professor of Radiation Oncology
Vice-Chair for Research
Cancer Biology Division Director
Department of Radiation Oncology
Washington University School of Medicine
ST. LOUIS, MISSOURI

Christin E. Burd, PhD
Professor
Department of Molecular Genetics
The Ohio State University
COLUMBUS, OHIO

Howard Y. Chang, MD, PhD
Howard Hughes Medical Institute Investigator
Director, Center for Personal Dynamic Regulomes
Virginia and D.K. Ludwig Professor of Cancer Genomics
Professor of Dermatology and Genetics
Stanford University School of Medicine
STANFORD, CALIFORNIA

Chuan He, PhD
Howard Hughes Medical Institute Investigator
John T. Wilson Distinguished Service Professor of Chemistry, Biochemistry, and Molecular Biology
The University of Chicago
CHICAGO, ILLINOIS

Peter P. Lee, MD
Billy Wilder Endowed Professor of Immuno-Oncology
Chair, Department of Immuno-Oncology
Professor, Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
DUARTE, CALIFORNIA

Ming Li, PhD
Member, Immunology Program, Sloan Kettering Institute
Professor, Gerstner Sloan Kettering Graduate School
Professor, Weill Cornell Graduate School of Medical Sciences
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Ivan P. Maillard, MD, PhD
Head of the Division of Hematologic Malignancies
Department of Medicine
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Nickolas Papadopoulos, PhD
Professor of Oncology and Pathology
Director of Translational Genetics
Ludwig Center for Cancer Genetics and Therapeutics
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
BALTIMORE, MARYLAND

David S. Pellman, MD
Howard Hughes Medical Institute Investigator
Professor of Cell Biology
Harvard Medical School
Margaret M. Dyson Professor of Pediatric Oncology
Dana-Farber Cancer Institute/ Boston Children's Hospital
BOSTON, MASSACHUSETTS

Theodora S. Ross, MD, PhD
Vice President, Early Oncology Research and Development
Bay Area Site Head
AbbVie, Inc.
SOUTH SAN FRANCISCO, CALIFORNIA

Stephen T. Smale, PhD
Distinguished Professor, Microbiology, Immunology, and Molecular Genetics
Sherie L. and Donald G. Morrison Chair, Molecular Immunology
University of California, Los Angeles
LOS ANGELES, CALIFORNIA

Benjamin P. Tu, PhD
Howard Hughes Medical Institute Investigator
University of Texas Southwestern Presidential Scholar
Martha Steiner Professorship in Medical Research
W.W. Caruth, Jr. Scholar in Biomedical Research
Professor, Biochemistry
University of Texas Southwestern Medical Center
DALLAS, TEXAS

Founding Member

Ronald Levy, MD
Robert K. and Helen K. Summy Professor
Stanford University School of Medicine
STANFORD, CALIFORNIA

DAMON RUNYON-RACHLEFF

INNOVATION AWARD

CALIFORNIA

Ziyang Zhang, PhD*
Small molecule activators of GTP hydrolysis for mutant Ras-driven cancer at University of California, Berkeley

FLORIDA

Alex M. Jaeger, PhD*
William Raveis Charitable Fund Innovator
Engineering approaches to exploit MHC-II antigen presentation in cancer at H. Lee Moffitt Cancer Center, Tampa

MASSACHUSETTS

Lucas Farnung, PhD
Understanding the mechanistic basis of gene expression regulation by MLL complexes in cancers at Harvard Medical School, Boston

Ryan A. Flynn, MD, PhD
Tools to target novel cell surface ligands in cancer at Boston Children's Hospital, Boston

Max Jan, MD, PhD
Programming next-generation NK cell therapies using targeted protein degradation at Massachusetts General Hospital, Boston

Humsa S. Venkatesh, PhD*
Identifying and disrupting the bioelectric circuits driving brain cancer at Brigham and Women's Hospital, Boston

NEW YORK

Daniel J. Puleston, PhD*
Bakewell Foundation Innovator
A new platform to study cancer biology and therapy in humans at Icahn School of Medicine at Mount Sinai, New York

Elvin Wagenblast, PhD
Untangling the evolutionary dependency of childhood leukemia at Icahn School of Medicine at Mount Sinai, New York

PENNSYLVANIA

Fange Liu, PhD
Y chromosome proteins in sex bias of cancers in non-reproductive organs at University of Pennsylvania, Philadelphia

Sydney M. Shaffer, MD, PhD*
Bakewell Foundation Innovator
Spatially resolved cellular competition in oncogenesis at University of Pennsylvania, Philadelphia

**Initial Year*

DAMON RUNYON-RACHLEFF

INNOVATION AWARD STAGE 2 FUNDING

CALIFORNIA

Danielle Grotjahn, PhD
Nadia's Gift Foundation Innovator
Uncovering structural mechanisms of mitochondrial fragmentation in cancer by cellular cryo-electron tomography at Scripps Research, La Jolla

CONNECTICUT

Luisa F. Escobar-Hoyos, PhD
Understanding RNA splicing in tumor-cell adaptation and anti-tumor immunity at Yale University School of Medicine, New Haven

Mandar D. Muzumdar, MD
Targeting endocrine-exocrine signaling in pancreatic ductal adenocarcinoma progression at Yale University School of Medicine, New Haven

MARYLAND

Jamie B. Spangler, PhD*
Engineered multispecific down-regulating antibodies to advance cancer immunotherapy at Johns Hopkins University, Baltimore

MASSACHUSETTS

Nora Kory, PhD*
Targeting mitochondrial transporters in cancer at Harvard T.H. Chan School of Public Health, Boston

Srinivas R. Viswanathan, MD, PhD*
X marks the spot: exploring how X-chromosome alterations drive sex differences in cancer at Dana-Farber Cancer Institute, Boston

**Initial Year*

PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD COMMITTEE

CHAIR

Andrew L. Kung, MD, PhD
Chair, Department of Pediatrics
Lila Acheson Wallace Chair for Pediatric Research
Memorial Sloan Kettering Cancer Center
NEW YORK, NEW YORK

Scott A. Armstrong, MD, PhD
Senior Vice President for Drug Discovery and Chief Research Strategy Officer
President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Chair, Department of Pediatric Oncology
Dana-Farber Cancer Institute
Associate Chief, Division of Hematology/Oncology
Boston Children's Hospital
David G. Nathan Professor of Pediatrics
Harvard Medical School
BOSTON, MASSACHUSETTS

Lia Gore, MD
Professor of Pediatrics, Medical Oncology, and Hematology
University of Colorado Anschutz Medical Campus
Chief, Pediatric Hematology/Oncology/Bone Marrow Transplant
The Ergen Family Endowed Chair in Pediatric Oncology
Children's Hospital Colorado
Center for Cancer and Blood Disorders
AURORA, COLORADO

Mark E. Hatley, MD, PhD
Associate Member
Director, Molecular Oncology Division
Department of Oncology
St. Jude Children's Research Hospital
MEMPHIS, TENNESSEE

Tara O. Henderson, MD, MPH
Arthur and Marian Edelstein Professor of Pediatrics
Professor of Medicine
Director, Childhood Adolescent and Young Adult Survivorship Center
Co-Leader, Comprehensive Cancer Center Prevention and Control Program
Chief, Section of Pediatric Cancer and Blood Diseases, Chicagoland Children's Health Alliance
University of Chicago Medicine
CHICAGO, ILLINOIS

Crystal L Mackall MD, FAAP, FAACR
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and Medicine
Director, Stanford Center for Cancer Cell Therapy
Director, Parker Institute for Cancer Immunotherapy at Stanford
Co-Executive Director, Laboratory for Cell and Gene Medicine at Stanford
Associate Director, Stanford Cancer Institute
Stanford University
STANFORD, CALIFORNIA

Jeff Magee, MD, PhD
Elizabeth H. and James S. McDonnell III Professor of Pediatrics
Director, McDonnell Pediatric Cancer Center
Division of Pediatric Hematology and Oncology
Washington University School of Medicine
ST. LOUIS, MISSOURI

DAMON RUNYON-ST. JUDE

PEDIATRIC CANCER RESEARCH FELLOWSHIP AWARD

CALIFORNIA

Stanford University

Mohammad Balood, PhD*
Development and evaluation of T cell receptor (TCR)-based immunotherapy to target pediatric Acute Megakaryoblastic Leukemia with Tanja A. Gruber, MD, PhD

University of California, San Francisco

Philip T. Pauerstein, MD, PhD*§
Enhancing immune synapse formation with synthetic adhesion to overcome chimeric antigen receptor-T cell resistance in pediatric B cell malignancies with Wendell A. Lim, PhD

MASSACHUSETTS

Dana-Farber Cancer Institute

April A. Apfelbaum, PhD*
Investigation of receptor tyrosine kinase-independent mechanisms of FGFR1-mediated oncogenesis in pediatric gliomas with Pratiti Bandopadhayay, MBBS, PhD, and Keith Lignon, MD, PhD

Costanza Lo Cascio, PhD*
Investigating the neuronal regulation of radioresistance in diffuse midline gliomas with Mariella G. Filbin, MD, PhD

James J. Morrow, MD, PhD*§
Application of single-cell approaches to investigate the developmental origin and early transformation steps of osteosarcoma with Bradley E. Bernstein, MD, PhD

**Initial Year*
§Physician-Scientists



DAMON RUNYON

SCHOLARS PROGRAM FOR ADVANCING RESEARCH AND KNOWLEDGE (SPARK) AWARD COMMITTEE

CHAIR

Joseph R. Osborne, MD, PhD
Chief of Molecular Imaging and Therapeutics
Professor of Radiology
Weill Cornell Medicine
NEW YORK, NEW YORK

Janelle Ayres, PhD
Howard Hughes Medical Institute Investigator
Professor and Laboratory Head
Gene Expression Laboratory
Molecular and Systems Physiology Laboratory
NOMIS Center for Immunobiology and Microbial Pathogenesis
Salk Institute Legacy Chair
Salk Institute for Biological Studies
LA JOLLA, CALIFORNIA

J. Robert Beck, MD
Professor Emeritus
H.O. West and J.R. Wike Chair in Cancer Research
Fox Chase Cancer Center
PHILADELPHIA, PENNSYLVANIA

Kara McKinley, PhD
Freeman Hrabowski Scholar of the Howard Hughes Medical Institute
Assistant Professor of Stem Cell and Regenerative Biology
Stem Cell and Regenerative Biology Department
Harvard University
CAMBRIDGE, MASSACHUSETTS

Andrew R. Zinn, MD, PhD
Henry Ross Perot Distinguished Professor in Biomedical Science
Rolf Haberecht and Ute Schwarz Haberecht Dean
Graduate School of Biomedical Sciences
University of Texas Southwestern Medical Center
DALLAS, TEXAS

DAMON RUNYON

SCHOLARS PROGRAM FOR ADVANCING RESEARCH AND KNOWLEDGE (SPARK) AWARD

Sangita Chakraborty
with Lydia Finley, PhD at Memorial Sloan Kettering Cancer Center, New York

Katelyn B. King
with Kornelia Polyak, MD, PhD at Dana-Farber Cancer Institute, Boston

Jayati Mondal
with Andrew Wolfe, PhD at City University of New York Hunter College, New York

Carli J. Newman
with Christina M. Termini, PhD at Fred Hutchinson Cancer Center, Seattle

THANK YOU TO OUR DONORS

Your support this year enabled us to invest over **$22.5 million** in exceptional young scientists working across research disciplines to better prevent, diagnose, and treat all forms of cancer.

DONOR SPOTLIGHT

A conversation with Damon Runyon supporter David G. Schwartz

For David G. Schwartz, supporting Damon Runyon through the Broadway Tickets service is a family tradition. Begun by his grandfather and now carried on by his daughter Stefanie, the tradition combines their love of theater and faith in the lifesaving promise of cancer research.

How did your family first learn about our Broadway Tickets service?
As far back as I can remember, my family has supported Damon Runyon through the theater program as well as individual donations. My grandfather, Harry A. Schwartz, learned about the Foundation through his brother, Samuel Schwartz. I remember my parents driving my sister and me into the city to see Broadway shows. I believe I was 13 years old when I saw Zero Mostel in *A Funny Thing Happened on the Way to the Forum*.

What appeals to your family about Damon Runyon's mission?
All the money donated goes to scientific studies to eradicate cancer—it's a clear and worthwhile mission.

What is your favorite show you've seen through the Broadway Tickets service?
Hamilton.

As longtime donors, you've been able to attend Damon Runyon events over the years and meet some of our Awardees. What has stood out to you from those experiences?
Meeting and greeting Damon Runyon scientists is a true learning experience. Their enthusiasm and commitment to working day and night to discover potential causes and cures for cancer would inspire anyone.

What would you say to prospective donors or anyone who's considering becoming a Damon Runyon theater customer?
I would highly recommend the Broadway Tickets program to anyone with an appreciation for theater and a desire to further the mission of finding cures for cancer. Donors have the satisfaction of getting to see the finest Broadway has to offer while at the same time helping humanity with a tax-deductible donation.

Is there anything else you'd like to share about your longtime partnership with Damon Runyon?
Working with Marialice [the Director of the Broadway Tickets service] for so many years has been a joy! I consider her part of my family of friends.

2024 EVENTS

ANNUAL BREAKFAST

Damon Runyon's Annual Breakfast was held at the Metropolitan Club in New York on June 12 and raised more than $1.5 million to support our scientists. Emeritus Board Member Ken Langone, Chairman of Invemed Associates and Co-Founder of The Home Depot, was honored for his longstanding support of Damon Runyon and his shared commitment to investing in bold ideas with the potential to have transformational impact. Guests also heard research updates from Damon Runyon scientists Lydia Finley, PhD, and Rabi Upadhyay, MD, while Isabella Grabski, PhD, was named the Foundation's first Kenneth G. Langone Quantitative Biology Fellow in Mr. Langone's honor.

TIMMERMAN TRAVERSE

Through a new partnership with the Timmerman Traverse, an adventurous initiative that brings leaders and investors in biotech together to scale extraordinary physical—and philanthropic—heights, Biotech journalist, entrepreneur, and mountaineer Luke Timmerman led a team of 20 scientific luminaries who hiked to the summit of Mt. Kilimanjaro, the African continent's highest peak, in February. Prior to the expedition, the team trained for hiking at more than 19,000 feet above sea level, enlisted the support of friends and colleagues, and together raised nearly $1.2 million to benefit Damon Runyon's brave and bold cancer researchers.

CULTIVATION EVENTS

Throughout the year, Damon Runyon hosted several regional events across the country to highlight the work of our awardees for supporters in South Florida, the Hamptons, the Bay Area, and beyond. From our winter movie screening in Boca Raton to cocktails and conversation on an August evening in Sag Harbor to an inspiring discussion with a Nobel laureate and a final dress rehearsal at the San Francisco Opera this fall, these unique events provided an opportunity for donors and prospective donors to hear directly from Damon Runyon scientists pursuing innovative research with the potential to improve treatment, diagnosis, and prevention of all cancers.

WILLIAM RAVEIS
CHARITABLE FUND

WILLIAM RAVEIS CHARITABLE FUND EVENTS

The William Raveis Charitable Fund, the philanthropic arm of William Raveis Real Estate, hosts fundraising events throughout the year in support of Damon Runyon, primarily in Connecticut, New York, and Massachusetts. Since 2015, WRCF has raised more than $4 million for cancer research and sponsored over 20 Damon Runyon scientists. We are incredibly grateful to the Raveis family and the entire Raveis community for their continued support of Damon Runyon scientists.

SPONSORED AWARDS

We thank our individual, foundation, and corporate sponsors who have partnered with us to launch or provide continuing support for specific award programs.

DAMON RUNYON-RACHLEFF INNOVATION AWARDS

This award was established thanks to the vision and generosity of Debbie and Andy Rachleff.

BAKEWELL FOUNDATION INNOVATORS

Daniel J. Puleston, PhD
Icahn School of Medicine at Mount Sinai

Sydney M. Shaffer, MD, PhD
University of Pennsylvania

NADIA'S GIFT FOUNDATION INNOVATOR

Danielle Grotjahn, PhD
Scripps Research

WILLIAM RAVEIS CHARITABLE FUND INNOVATOR

Alex M. Jaeger, PhD
H. Lee Moffitt Cancer Center and Research Institute

DAMON RUNYON CLINICAL INVESTIGATOR AWARDS

This award was initially established in partnership with Eli Lilly and Company. In addition, it is supported by Accelerating Cancer Cures, a collaboration between Damon Runyon and leading biopharmaceutical companies.

BAKEWELL FOUNDATION CLINICAL INVESTIGATOR

Nathan Singh, MD
Washington University

BEN AND CATHERINE IVY FOUNDATION CLINICAL INVESTIGATOR

John R. Prensner, MD, PhD
University of Michigan

GORDON FAMILY CLINICAL INVESTIGATOR

Santosha A. Vardhana, MD, PhD
Memorial Sloan Kettering Cancer Center

LESLIE COHEN SEIDMAN CLINICAL INVESTIGATOR

Steven M. Corsello, MD
Stanford University School of Medicine

TIMMERMAN TRAVERSE CLINICAL INVESTIGATOR

Lachelle D. Weeks, MD, PhD
Dana-Farber Cancer Institute

DAMON RUNYON FELLOWSHIP AWARDS

The following awards are funded by donors who have generously endowed an award in perpetuity or sponsored an individual Fellow.

BAKEWELL FOUNDATION FELLOW

John Devany, PhD
Northwestern University

BERGER FOUNDATION FELLOWS

Antonio Cuevas-Navarro, PhD
Memorial Sloan Kettering Cancer Center

Catherine A. Freije, PhD
The Rockefeller University

CONNIE AND BOB LURIE FELLOWS*

Sagar Bhattacharya, PhD
University of California, San Francisco

Tadashi Manabe, MD, PhD
University of California, San Francisco

Fanglue Peng, PhD
University of California, San Francisco

David S. Roberts, PhD
Stanford University

Simon Sretenovic, PhD
Stanford University School of Medicine

Erron W. Titus, MD, PhD
University of California, San Francisco

Xiaowei Yan, PhD*
Stanford University School of Medicine

Qinheng Zheng, PhD
University of California, San Francisco

Ronghui Zhu, PhD
Gladstone Institutes

DALE F. AND BETTY ANN FREY FELLOW*

Marie R. Siwicki, PhD
University of Calgary

DAVID RYLAND FELLOW

Timothy J. Eisen, PhD
University of California, Berkeley

DEBORAH J. COLEMAN FELLOW*

Shreoshi Sengupta, PhD
Boston Children's Hospital

DENNIS AND MARSHA DAMMERMAN FELLOW*

Michael V. Gormally, MD, PhD
Memorial Sloan Kettering Cancer Center

FAYEZ SAROFIM FELLOW*

Pu Zheng, PhD
Whitehead Institute for Biomedical Research

FRATERNAL ORDER OF EAGLES FELLOW*

Bo Gu, PhD
California Institute of Technology

HOWARD HUGHES MEDICAL INSTITUTE (HHMI) FELLOWS

R. Camille Brewer, PhD
University of California, Berkeley

Ben F. Brian, PhD
University of California, Berkeley

Hui (Vivian) Chiu, PhD
Yale University

Edward M. C. Courvan, PhD
University of Colorado Boulder

Laura Crowley, PhD
Stanford University

Mingjian Du, PhD
Columbia University

Brendan Floyd, PhD
Stanford University

Nicole M. Hoitsma, PhD
University of Colorado Boulder

Lucia Ichino, PhD
Stanford University

Grace E. Johnson, PhD
Princeton University

Grant A. King, PhD
Fred Hutchinson Cancer Center

Archana Krishnamoorthy, PhD
Dana-Farber Cancer Institute

Senén D. Mendoza, PhD
Massachusetts Institute of Technology

Rebecca S. Moore, PhD
University of Pennsylvania

Ryan Y. Muller, PhD
Whitehead Institute for Biomedical Research

Dylan M. Parker, PhD
University of Colorado Boulder

Nalin Ratnayeke, PhD
Memorial Sloan Kettering Cancer Center

Ian J. Roney, PhD
Massachusetts Institute of Technology

Rocío D. M. Saavedra-Peña, PhD
Harvard Medical School

Joshua B. Sheetz, PhD
University of California, Berkeley

Wenzhi Song, PhD
The Rockefeller University

Zeda Zhang, PhD
Memorial Sloan Kettering Cancer Center

Xiphias Ge Zhu, PhD
Brigham and Women's Hospital

ILLINI 4000 FELLOW

Edie I. Crosse, PhD
Fred Hutchinson Cancer Center

KENNETH G. AND ELAINE A. LANGONE FELLOW*

Wen Mai Wong, PhD
Salk Institute

LALLAGE FEAZEL WALL FELLOW*

Hannah A. Grunwald, PhD
Harvard Medical School

LORRAINE W. EGAN FELLOW*

Claudia A. Rivera Cifuentes, PhD
National Institutes of Health

MARION ABBE FELLOW*

Jinchun Wu, PhD
University of California, San Diego

THE MARK FOUNDATION FOR CANCER RESEARCH FELLOWS

Yajing Gao, PhD
University of California, Los Angeles

Siqi Li, PhD
Fred Hutchinson Cancer Center

MEGHAN E. RAVEIS FELLOW

Anders B. Dohlman, PhD
Dana-Farber Cancer Institute

MERCK FELLOWS

Gabriel Cavin-Meza, PhD
University of California, Berkeley

Madi Y. Cissé, PhD
Harvard T.H. Chan School of Public Health

Isabella Fraschilla, PhD
Massachusetts Institute of Technology

Cayla E. Jewett, PhD
Johns Hopkins University School of Medicine

Heidi E. Klumpe, PhD
Boston University

Sangwoo Park, PhD
Massachusetts General Hospital

Sarah L. Price, PhD
Vanderbilt University Medical Center

Akanksha Thawani, PhD
University of California, Berkeley

NATIONAL MAH JONGG LEAGUE FELLOWS

Xin Gu, PhD
Harvard Medical School

Brooke D. Huisman, PhD
Dana-Farber Cancer Institute

Georgia R. Squyres, PhD
California Institute of Technology

Catherine Triandafillou, PhD
University of Pennsylvania

Wendy Xueyi Wang, PhD
Broad Institute

PHILIP O'BRYAN MONTGOMERY, JR., MD, FELLOW

Manuel Osorio Valeriano, PhD
Harvard Medical School

REBECCA RIDLEY KRY FELLOW*

Titas Sengupta, PhD
Princeton University

RHEE FAMILY FELLOW

Yoshiki Sakai, PhD
University of California, Berkeley

ROBERT A. SWANSON FAMILY FELLOW

Expery O. Omollo, PhD
Massachusetts Institute of Technology

ROBERT BLACK FELLOWS

Rico C. Ardy, PhD
Memorial Sloan Kettering Cancer Center

Debadrita Bhattacharya, PhD
Stanford University School of Medicine

Elizabeth R. Hughes, PhD
Duke University

Jordan B. Jastrab, PhD
Brigham and Women's Hospital

Erik Van Dis, PhD
University of Washington

SUZANNE AND BOB WRIGHT FELLOW*

Chaiheon Lee, PhD
Broad Institute

TIMMERMAN TRAVERSE FELLOWS

Tamar Kavlashvili, PhD
Memorial Sloan Kettering Cancer Center

Shaohua Zhang, PhD
University of California, San Francisco

WALTER ISAACSON FELLOW

Aaron E. Lin, PhD
Princeton University

**In perpetuity*

DAMON RUNYON-DALE F. FREY AWARD FOR BREAKTHROUGH SCIENTISTS

This award supports those Fellows who have greatly exceeded Damon Runyon's highest expectations with an additional investment. It was established in honor of late former Damon Runyon Board Chair Dale F. Frey.

NATIONAL MAH JONGG LEAGUE BREAKTHROUGH SCIENTIST

Erin E. Duffy, PhD
Harvard Medical School

DAMON RUNYON PHYSICIAN-SCIENTIST TRAINING AWARDS

This award was established thanks to the generosity of Damon Runyon Emeritus Board Members Leon G. Cooperman and Michael L. Gordon.

DAVID M. LIVINGSTON, MD, PHYSICIAN-SCIENTIST

Mounica Vallurupalli, MD
Dana-Farber Cancer Institute

THE MARK FOUNDATION FOR CANCER RESEARCH PHYSICIAN-SCIENTISTS

Nicole M. Cruz, MD
The Rockefeller University

Rebecca L. Zon, MD
Dana-Farber Cancer Institute

WILLIAM G. KAELIN, JR., MD, PHYSICIAN-SCIENTIST

Albert E. Kim, MD
Massachusetts General Hospital

DAMON RUNYON QUANTITATIVE BIOLOGY FELLOWSHIP AWARDS

The following awards are funded by donors who generously sponsor an individual Quantitative Biology Fellow.

KENNETH G. LANGONE QUANTITATIVE BIOLOGY FELLOW

Isabella N. Grabski, PhD
New York Genome Center

LESLIE COHEN SEIDMAN QUANTITATIVE BIOLOGY FELLOW

Ahmed Roman, PhD
Dana-Farber Cancer Institute

DAMON RUNYON-JAKE WETCHLER AWARD FOR PEDIATRIC INNOVATION

This $10,000 award is named in honor of Jake Wetchler, who died at age 20 after a heroic fight against two different cancers.

Yapeng Su, PhD
Fred Hutchinson Cancer Research Center

ACCELERATING CANCER CURES

Accelerating Cancer Cures is supported by leading biopharmaceutical companies committed to finding new cures for cancer. Thank you to Genentech, Merck, AbbVie, Amgen, and Novartis for partnering with us to support the Damon Runyon Clinical Investigator Award.

In conjunction with this initiative, the Accelerating Cancer Cures Research Symposium brings together our translational researchers with industry leaders to foster communication and collaboration to help speed progress against cancer.

The 2024 Accelerating Cancer Cures Research Symposium was held on Thursday, March 7, at the Abbvie campus in South San Francisco. We thank Abbvie and all our ACC partners for their support and commitment to the next generation of clinical investigators.

BROADWAY PREMIER CIRCLE

The Broadway Premier Circle is a group of loyal Damon Runyon Broadway Tickets customers who have made a special donation in support of cancer research. The Premier Circle offers members priority access to tickets and other benefits.

Sharman and David Altshuler, MD
Barbara Lieb Baumstein
Isabel and Steven Berg
Ann and Frank Bumstead
Samuel T. Cohen
Dorothy D'Amato
Jane and Larry Droppa
Jill and Mark Fishman
Mary Ann Frenzel
Ronald S. Gross
Andre Hunter
Jennifer and James H. Kimenker
Richard A. Konigsberg
Ellen S. Lane
Marcia and William Guy Levy
Susan and Martin Lipton
Clare and Kenneth Livak, PhD
Russell C. Minkoff
Sylvia and Norman Samet
Linda and Jerry Saslow
Suzy Sang Shechtman
Marilyn and Scott Urdang
Judith and Peter Wasserman
Janet M. Widra, PhD
Jami and Owen Witte, MD

WAYS TO GIVE

ONLINE

damonrunyon.org/donate

PHONE

1.877.7CANCER or 1.877.722.6237
9 am–5 pm ET, Monday to Friday

MAIL

One Exchange Plaza, 55 Broadway, Suite 302
New York, NY 10006

ESTATE PLANNING

Visit our website for more information:
damonrunyon.org/get-involved

DAMON RUNYON BROADWAY TICKETS

Damon Runyon Broadway Tickets offers Broadway's best seats and the opportunity to support cutting-edge cancer research at the same time. Orchestra seats are available for even the most popular shows.

Join our **Premier Circle** to enjoy benefits like priority access to tickets before they go on sale each month, and more.

Our **Gift Certificates** are perfect for holiday gifts, as well as birthdays, anniversaries, or any occasion—a fun night and a meaningful gift.

Call us for tickets at 212.455.0550 between 9 am–5 pm ET, Monday to Friday. Purchase tickets online at **damonrunyon.org/broadway**

FINANCIAL SUMMARY FISCAL YEAR 2024

As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2024.

For our complete audited financial statements, please visit our website at **damonrunyon.org**

TOTAL REVENUE

30.5%	Investment Return
49.9%	Contributions
6.3%	Misc. Income
13.0%	Bequests & Trusts
0.3%	Damon Runyon Broadway Tickets

TOTAL OPERATING EXPENSES

86.6%	Programs
8.8%	Fundraising
4.6%	General Administration

SUMMARY OF BALANCE SHEETS

	2023	2024
Total Assets	$147,680,687	$160,511,709
Total Liabilities	$32,920,972	$35,205,374
Total Net Assets	$114,759,715	$125,306,335

CHARITY NAVIGATOR ★★★★ Four Star Charity

100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead with revenue from Damon Runyon Broadway Tickets and our endowment.

100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

Cover Illustration by Ollie Hirst

DAMON RUNYON
CANCER RESEARCH
FOUNDATION

Funding brave and bold.